The novel potent GSK3 inhibitor AF3581 reverts fragile X syndrome phenotype
- 1 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (6), 839-849
- https://doi.org/10.1093/hmg/ddab251
Abstract
Glycogen-synthase kinase 3 (GSK3) is a kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK3 has been linked to several disease conditions such as fragile X syndrome (FXS). Recent evidences demonstrating an increased activity of GSK3 in murine models of FXS, suggest that dysregulation/hyperactivation of the GSK3 path should contribute to FXS development. A likely possibility could be that in FXS there is a functional impairment of the upstream inhibitory input over GSK3 thus making overactive the kinase. Since GSK3 signaling is a central regulatory node for critical neurodevelopmental pathways, understanding the contribution of GSK3 dysregulation to FXS, may provide novel targets for therapeutic interventions for this disease. In this study we used AF3581, a potent GSK3 inhibitor that we recently discovered, in an in vivo FXS mouse model to elucidate the crucial role of GSK3 in specific behavioral patterns (locomotor activity, sensorimotor gating and social behavior) associated with this disease. All the behavioral alterations manifested by Fmr1 knockout mice were reverted after a chronic treatment with our GSK3 inhibitor, confirming the importance of this pathway as a therapeutic target.This publication has 46 references indexed in Scilit:
- Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatmentBrain Research, 2011
- Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic‐like responsesAutism Research, 2011
- GSK3 signalling in neural developmentNature Reviews Neuroscience, 2010
- Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndromeInternational Journal of Neuropsychopharmacology, 2010
- GSK3: a multifaceted kinase in Wnt signalingTrends in Biochemical Sciences, 2010
- Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of Fragile X syndromeBiochemical Pharmacology, 2010
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndromeNeuroscience Letters, 2009
- Elevated glycogen synthase kinase-3 activity in Fragile X mice: Key metabolic regulator with evidence for treatment potentialNeuropharmacology, 2009
- Absence of expression of the FMR-1 gene in fragile X syndromeCell, 1991